Eversept Partners LP raised its position in Illumina, Inc. (NASDAQ:ILMN) by 4,416.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,290 shares of the life sciences company’s stock after purchasing an additional 17,885 shares during the quarter. Illumina accounts for approximately 1.9% of Eversept Partners LP’s portfolio, making the stock its 15th largest holding. Eversept Partners LP’s holdings in Illumina were worth $6,733,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in ILMN. Broderick Brian C raised its holdings in shares of Illumina by 0.3% during the 2nd quarter. Broderick Brian C now owns 13,240 shares of the life sciences company’s stock valued at $4,874,000 after buying an additional 36 shares during the period. Foresight Wealth Management LLC grew its position in shares of Illumina by 4.2% in the 2nd quarter. Foresight Wealth Management LLC now owns 972 shares of the life sciences company’s stock worth $358,000 after acquiring an additional 39 shares in the last quarter. Bbva USA Bancshares Inc. grew its position in shares of Illumina by 2.0% in the 2nd quarter. Bbva USA Bancshares Inc. now owns 2,020 shares of the life sciences company’s stock worth $743,000 after acquiring an additional 40 shares in the last quarter. Greenleaf Trust grew its position in shares of Illumina by 0.6% in the 2nd quarter. Greenleaf Trust now owns 6,691 shares of the life sciences company’s stock worth $2,463,000 after acquiring an additional 42 shares in the last quarter. Finally, Nachman Norwood & Parrott Inc grew its position in shares of Illumina by 3.4% in the 2nd quarter. Nachman Norwood & Parrott Inc now owns 1,360 shares of the life sciences company’s stock worth $501,000 after acquiring an additional 45 shares in the last quarter. Institutional investors own 90.92% of the company’s stock.
In other news, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction on Monday, June 17th. The stock was sold at an average price of $349.28, for a total transaction of $3,492,800.00. Following the transaction, the senior vice president now owns 65,994 shares in the company, valued at $23,050,384.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $358.15, for a total value of $1,181,895.00. Following the transaction, the director now owns 275,916 shares in the company, valued at approximately $98,819,315.40. The disclosure for this sale can be found here. Insiders have sold 56,198 shares of company stock worth $17,773,470 in the last quarter. 0.38% of the stock is currently owned by corporate insiders.
Shares of Illumina stock traded up $3.44 on Friday, reaching $300.97. 123,728 shares of the company were exchanged, compared to its average volume of 911,882. The stock has a fifty day moving average price of $287.49 and a 200-day moving average price of $313.82. The firm has a market capitalization of $40.58 billion, a price-to-earnings ratio of 52.62, a price-to-earnings-growth ratio of 2.57 and a beta of 1.09. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a fifty-two week low of $263.30 and a fifty-two week high of $380.76.
Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. The company had revenue of $838.00 million for the quarter, compared to analyst estimates of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. Illumina’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.43 earnings per share. On average, equities analysts anticipate that Illumina, Inc. will post 6.04 earnings per share for the current fiscal year.
Several brokerages have weighed in on ILMN. Credit Suisse Group reaffirmed a “buy” rating and set a $340.00 target price on shares of Illumina in a research note on Wednesday, July 31st. Piper Jaffray Companies cut their target price on Illumina from $382.00 to $348.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 30th. UBS Group lifted their target price on Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Deutsche Bank cut their target price on Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a research note on Friday, July 12th. Finally, ValuEngine raised Illumina from a “hold” rating to a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company. Illumina currently has an average rating of “Buy” and a consensus price target of $330.92.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Why do commodities matter?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.